Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

NCT00069992 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Closed due to competing protocols

Conditions

Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes

Interventions

RADIATION: Total Body Irradiation
DRUG: Fludarabine
DRUG: Campath 1H

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]